3009 boulevard de la Concorde East
Suite 102
Laval, QC H7E 2B5
Canada
450-687-2262
https://www.acastipharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Prashant Kohli | CEO & Director | 358,41k | N/D | 1972 |
Mr. Robert J. DelAversano CPA | Principal Financial & Accounting Officer | N/D | N/D | 1972 |
Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer | N/D | N/D | 1962 |
Mr. Amresh Kumar Ph.D. | VP of Program Management | N/D | N/D | 1980 |
Ms. Carrie D'Andrea | VP of Clinical Operations | N/D | N/D | 1972 |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
L'ISS Governance QualityScore di Acasti Pharma Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.